A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02347657|
Recruitment Status : Completed
First Posted : January 27, 2015
Results First Posted : June 12, 2018
Last Update Posted : June 12, 2018
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cystic Fibrosis||Drug: VX-661 Plus Ivacaftor Combination Drug: Ivacaftor Drug: VX-661 Plus Ivacaftor Combination Placebo Drug: Ivacaftor placebo||Phase 3|
Expanded Access : Vertex Pharmaceuticals Incorporated has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||510 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|
|Actual Study Start Date :||January 2015|
|Actual Primary Completion Date :||January 20, 2017|
|Actual Study Completion Date :||January 20, 2017|
Placebo Comparator: Placebo
Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
Drug: VX-661 Plus Ivacaftor Combination Placebo
FDC tablet, oral use
Drug: Ivacaftor placebo
Tablet, oral use
VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
Drug: VX-661 Plus Ivacaftor Combination
FDC tablet, oral use
Tablet, oral use
- Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24 [ Time Frame: Day 1, Through Week 24 ]FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
- Relative Change From Baseline (Day 1) in ppFEV1 Through Week 24 [ Time Frame: Day 1, Through Week 24 ]FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
- Number of Pulmonary Exacerbations Per Year [ Time Frame: Day 1 through Week 24 ]Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Pulmonary exacerbation events per year (48 weeks) were reported.
- Absolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 24 [ Time Frame: Day 1, Week 24 ]BMI was defined as weight in kilograms (kg) divided by height in square meter (m^2).
- Absolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24 [ Time Frame: Day 1, Through Week 24 ]The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Week 28 ]AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.
- Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24 [ Time Frame: Day 1 through Week 24 ]Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Time to event data was not collected and instead, Number of Subjects with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
- Absolute Change From Baseline (Day 1) in Sweat Chloride Through Week 24 [ Time Frame: Day 1, Through Week 24 ]Sweat samples were collected using an approved collection device.
- Absolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening) [ Time Frame: Day 1, Week 24 ]BMI was defined as weight in kg divided by height in m^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).
- Absolute Change From Baseline (Day 1) in Body Weight at Week 24 [ Time Frame: Day 1, Week 24 ]
- Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661 and M2-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA) [ Time Frame: Pre-morning dose on Week 16 ]This outcome was not planned to be assessed in Placebo arm.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Homozygous for the F508del CFTR mutation, genotype to be confirmed at the Screening Visit
- Confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis
- Forced expiratory volume at one second (FEV1) ≥40% and ≤90% of predicted normal for age, sex, and height during screening
- Stable CF disease as judged by the investigator
- Willing to remain on a stable CF medication regimen through Week 24 or, if applicable, the Safety Follow up Visit
- History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.
- An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug)
- Pregnant or nursing females (females of childbearing potential must have a negative pregnancy test at Screening and Day 1)
- Sexually active participants of reproductive potential who are not willing to follow the contraception requirements
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02347657
Documents provided by Vertex Pharmaceuticals Incorporated:
|Responsible Party:||Vertex Pharmaceuticals Incorporated|
|Other Study ID Numbers:||
|First Posted:||January 27, 2015 Key Record Dates|
|Results First Posted:||June 12, 2018|
|Last Update Posted:||June 12, 2018|
|Last Verified:||May 2018|
Homozygous for the F508del CFTR Mutation
Digestive System Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action